Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insmed Growth Agent iPlex Joins Tercica’s Increlex With Orphan Exclusivity

Executive Summary

Insmed is focusing on the dosing schedule of its growth hormone treatment iPlex to distinguish it from Tercica's competing product Increlex

You may also be interested in...



Oncology, CNS Agents May Dominate 2006 NME Approvals; 2005 Total Is 18

The first half of 2006 could bring at least five novel oncologic approvals, including three for hematologic cancers

Oncology, CNS Agents May Dominate 2006 NME Approvals; 2005 Total Is 18

The first half of 2006 could bring at least five novel oncologic approvals, including three for hematologic cancers

Tercica Finishes First With Increlex Orphan Approval; Insmed Left In Dust?

FDA will decide a battle for orphan drug exclusivity in the extreme short stature market between Tercica's Increlex and Insmed's SomatoKine if and when Insmed's agent is approved, Tercica predicted

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel